Skip to main content

Table 2 Primary and secondary endpoints

From: The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of OSteoporosis (PaVOS)- study protocol for a randomized controlled trial

  Measurement Site Time (months)
Primary endpoints
 Δ Bone mineral density DXA Total hip
Spinal region
12
Secondary endpoints
 Δ Bone mineral density DXA Total hip
Spinal region
6, 18, and 24
 Δ Bone microarchitecture HR-pQCT Distal radius
Distal tibia
6, 12, 18, and 24
 Δ Bone biomarkers P1NP
CTX, sclerostin
Serum 3, 6, 12, 18, and 24
 Δ Physical biomarkers TUG
SPPB
  3, 6, 12, 18, and 24
Dynamometer Hand grip
Nottingham power rig Leg extensor
 Δ Quality of life EQ-5D   12 and 24
 Δ Fear of falling FES-I   12 and 24
 Physical activity IPAQ   0, 12, and 24
 Adherence to WBV Training logbook   Continuously
 Falls Falls calendar   Continuously
  1. Δ change from baseline; Time is measured in months; DXA dual-energy x-ray absorptiometry; HR-pQCT high-resolution peripheral quantitative computed tomography; P1NP procollagen type-1 amino-terminal propeptide; CTX carboxy-terminal type-1 collagen crosslinks; TUG Timed Up and Go; SPPB Short Physical Performance Battery; FES-I Falls Efficacy Scale International; IPAQ The International Physical Activity Questionnaire; EQ-5D EuroQoL 5-dimension, 5-level questionnaire, WBV whole-body vibration